Last reviewed · How we verify
doxorubicin, cyclophosphamide, paclitaxel, trastuzumab
doxorubicin, cyclophosphamide, paclitaxel, trastuzumab is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 2 development.
At a glance
| Generic name | doxorubicin, cyclophosphamide, paclitaxel, trastuzumab |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer (PHASE3)
- Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (PHASE3)
- Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (PHASE2)
- Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) (PHASE2)
- Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- doxorubicin, cyclophosphamide, paclitaxel, trastuzumab CI brief — competitive landscape report
- doxorubicin, cyclophosphamide, paclitaxel, trastuzumab updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about doxorubicin, cyclophosphamide, paclitaxel, trastuzumab
What is doxorubicin, cyclophosphamide, paclitaxel, trastuzumab?
doxorubicin, cyclophosphamide, paclitaxel, trastuzumab is a Small molecule drug developed by Merck Sharp & Dohme LLC.
Who makes doxorubicin, cyclophosphamide, paclitaxel, trastuzumab?
doxorubicin, cyclophosphamide, paclitaxel, trastuzumab is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).
What development phase is doxorubicin, cyclophosphamide, paclitaxel, trastuzumab in?
doxorubicin, cyclophosphamide, paclitaxel, trastuzumab is in Phase 2.